M08.20
Juvenile rheumatoid arthritis with systemic onset, unspecified site
Clinical Classification Guidelines
Medical Intelligence & Overview
Juvenile Rheumatoid Arthritis (JRA), also known as Juvenile Idiopathic Arthritis (JIA), is a chronic autoimmune condition affecting children under 16 years old. The subtype classified under ICD-10 code M08.20 is characterized by systemic onset, meaning the disease impacts the whole body rather than just one joint or area. This form is unpredictable and can cause widespread symptoms, affecting various organs and systems. Recognizing its signs early is crucial for managing the condition effectively and improving quality of life.
Causes & Symptoms
Clinical Causes: The exact cause of juvenile systemic onset JRA is unknown. It involves an abnormal immune system response where the body mistakenly attacks its own tissues. Genetic factors may contribute, with certain genes linked to increased risk. Environmental factors, such as infections, might trigger the onset in genetically predisposed children.
Key Symptoms: Persistent high fever, often spiking in the evenings A rash that appears as pink or red spots, typically on the trunk or limbs Swollen and painful joints, which may affect multiple areas simultaneously Swelling of the liver, spleen, or lymph nodes Fatigue and irritability Loss of appetite and weight loss Muscle pain or stiffness In some cases, inflammation of the eyes (iritis or uveitis) which can lead to vision problems if untreated
Diagnostic & Treatment
Diagnosis Path: Diagnosing systemic juvenile rheumatoid arthritis involves a combination of medical history, physical examinations, and laboratory tests. No single test confirms the condition, but features such as persistent fever, rash, and joint swelling guide the diagnosis. Common tests include blood counts, ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), and imaging studies like X-rays or MRI scans to assess joint involvement. An ophthalmologic exam is often recommended to check for eye inflammation. The diagnosis is clinical and made after ruling out other conditions that could cause similar symptoms.
Treatment Protocols: While there is no cure for juvenile systemic onset JRA, various treatments aim to control inflammation, reduce symptoms, and prevent joint damage. Approaches include: - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): To help decrease pain and inflammation. - Corticosteroids: For severe symptoms, steroids may be used short-term or as a long-term solution. - Disease-Modifying Antirheumatic Drugs (DMARDs): Such as methotrexate, to alter the disease course. - Biologic agents: Target specific parts of the immune system to reduce inflammation. - Physical therapy and occupational therapy: To maintain joint function and improve mobility. - Regular monitoring and supportive care are essential, involving a multidisciplinary team to manage the diverse symptoms and prevent complications.
Clinical Advice & FAQs
Billing Guidance
Is M08.20 a billable ICD-10 code?
Yes, M08.20 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M08.20?
Clinical documentation must specify the nature of Juvenile rheumatoid arthritis with systemic onset, unspecified site and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
